| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
OGP receptor (a putative G-protein-coupled receptor) and Src kinase (inhibitor activity). OGP(10-14) binds to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. It also acts as a Src inhibitor, contributing to its osteogenic effects.
|
|---|---|
| ln Vitro |
Osteogenic Growth Peptide (10-14) (OGP(10-14)) stimulates proliferation and differentiation in fibroblast and osteoblast cell lines[3]. Osteogenic Growth Peptide (10-14) stimulates TPO-primed M07-e cells differentiation through RhoA/ TGFβ1/SFKs signaling pathway. In particular Historphin functions as a Src inhibitor, displaying the same effects of PP2[4].
OGP(10-14) is a pentapeptide (YGFGG) corresponding to residues 10-14 of OGP. It binds to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. OGP(10-14) acts as a Src inhibitor and is a potent mitogen and stimulator of osteogenesis and hematopoiesis. It stimulates proliferation of osteoblastic cells and enhances bone formation in vitro and in vivo. |
| ln Vivo |
In mice and rats, administration of Osteogenic Growth Peptide (10-14) (OGP(10-14)) promotes fracture healing and enhances trabecular bone density and bone formation[1].
OGP(10-14) increases bone formation and trabecular bone density and stimulates fracture healing when administered to mice and rats. It has been shown to promote bone regeneration, accelerate fracture healing, and increase bone mineral density. The compound is a potent mitogen and stimulates hematopoiesis. These effects are mediated through the OGP receptor and the Gi-protein-MAP kinase signaling pathway. |
| Enzyme Assay |
Cell-free receptor binding assays for the OGP receptor can be performed using membranes from cells expressing the OGP receptor. Membranes are incubated with a radiolabeled OGP analog (e.g., 125I-OGP) and increasing concentrations of unlabeled OGP(10-14) (0.01-10,000 nM) in binding buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 0.1% BSA) for 60-90 min at 25degC. Bound radioactivity is separated by GF/B filtration. IC50 and Ki are calculated. For Src inhibition, cell-free Src kinase assays are performed using recombinant Src enzyme and ATP with increasing concentrations of OGP(10-14).
|
| Cell Assay |
Osteoblastic cell lines (e.g., MC3T3-E1, SaOS-2) or primary osteoblasts are seeded and treated with OGP(10-14) at concentrations of 0.1-100 uM for 24-72 hours. Cell proliferation is assessed by MTT, BrdU incorporation, or cell counting. Alkaline phosphatase activity (an early marker of osteoblast differentiation) is measured using a colorimetric assay. Matrix mineralization is assessed by Alizarin Red S staining after 14-21 days of treatment. OPG (osteoprotegerin) and RANKL expression (markers of osteoclast regulation) are measured by qRT-PCR or ELISA. Activation of MAP kinase signaling (ERK1/2) is assessed by Western blot.
|
| Animal Protocol |
Male or female rodents (mice or rats) are used for bone formation and fracture healing studies. OGP(10-14) is dissolved in sterile saline or PBS. For fracture healing, a standardized fracture is created in a long bone (e.g., femur or tibia). OGP(10-14) is administered locally at the fracture site (via injection or implantation of a slow-release delivery system) or systemically by intraperitoneal injection (10-100 ug/kg) daily for 2-4 weeks. Fracture healing is assessed by radiography, micro-CT, biomechanical testing (three-point bending), and histomorphometry. Bone formation is assessed by dynamic histomorphometry after calcein double labeling. For bone density studies, OGP(10-14) is administered systemically to normal or osteoporotic animals for 4-8 weeks. Trabecular bone density is assessed by micro-CT. Serum markers of bone formation (P1NP, osteocalcin) and resorption (CTX-1) are measured by ELISA.
|
| ADME/Pharmacokinetics |
No specific PK data are reported for OGP(10-14). Molecular weight: 499.52 (C24H29N5O7). CAS 105250-85-9. The compound is a pentapeptide. It is not orally bioavailable and has a short plasma half-life (minutes) due to rapid degradation by peptidases. For in vivo studies, it is typically administered by injection (i.p., s.c., or local). Solubility: DMSO (6 mg/mL), water (90 mg/mL). Storage: -20degC, dry, sealed. Peptide stability is improved by formulation in sterile saline and immediate use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are reported for OGP(10-14). In published in vivo studies in mice and rats at doses used for bone formation (10-100 ug/kg), no signs of toxicity (weight loss, behavioral changes, or organ toxicity) were observed. The compound is a naturally occurring peptide fragment and is considered safe at research doses. Comprehensive toxicological assessments have not been performed. No FDA approval. Not a drug. For research use only.
|
| References |
|
| Additional Infomation |
Other information: OGP(10-14) (CAS 105250-85-9) is a research-grade peptide, not FDA-approved. It is the C-terminal pentapeptide fragment (YGFGG) of osteogenic growth peptide. It retains full OGP-like bioactivity, stimulating bone formation, hematopoiesis, and fracture healing. It binds to the OGP receptor and activates Gi-protein-MAP kinase signaling. It also acts as a Src inhibitor. Synonyms: Historphin, OGP(10-14). For research use only.
|
| Molecular Formula |
C24H29N5O7
|
|---|---|
| Molecular Weight |
499.52
|
| Exact Mass |
499.207
|
| CAS # |
105250-85-9
|
| PubChem CID |
147077
|
| Appearance |
White to off-white solid powder
|
| Density |
1.352g/cm3
|
| Boiling Point |
1028ºC at 760mmHg
|
| Flash Point |
575.5ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
0.686
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
36
|
| Complexity |
764
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)NCC(=O)O)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)N
|
| InChi Key |
BGFPKYKDLYYTJH-OALUTQOASA-N
|
| InChi Code |
InChI=1S/C24H29N5O7/c25-18(10-16-6-8-17(30)9-7-16)23(35)27-13-21(32)29-19(11-15-4-2-1-3-5-15)24(36)28-12-20(31)26-14-22(33)34/h1-9,18-19,30H,10-14,25H2,(H,26,31)(H,27,35)(H,28,36)(H,29,32)(H,33,34)/t18-,19-/m0/s1
|
| Chemical Name |
2-[[2-[[(2S)-2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetyl]amino]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 8.93 mg/mL (17.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.9 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.9 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.89 mg/mL (1.78 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0019 mL | 10.0096 mL | 20.0192 mL | |
| 5 mM | 0.4004 mL | 2.0019 mL | 4.0038 mL | |
| 10 mM | 0.2002 mL | 1.0010 mL | 2.0019 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
